IP Library Granted Patent US 10,377,992
Granted Patent B2
US 10,377,992 · App. 15/256,228 · Granted Aug 13, 2019

Bacteriophage and methods of making and using

Inventors: Dongmei Xu (Glen Allen, VA); Elisabeth Miller (Chesterfield, VA); James Arthur Strickland (Richmond, VA); Ujwala Warek (Chester, VA); Steven Hagens (Bennekom, NL)
Assignees: Altria Client Services LLC; Micreos BV
C12N7/00A24B15/20C07K14/005C12N9/2462C12Y302/01017C12N2795/00021C12N2795/00022C12N2795/00031C12N2795/12031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,377,992
App. No.
15/256,228
Granted
Aug 13, 2019
Kind
B2
Abstract

Bacteriophage are provided, and methods of making and using the bacteriophage also are provided. The bacteriophage can be provided in a tobacco product, where the bacteriophage reduces the number of viable bacteria in the tobacco product and includes a nucleic acid sequence encoding an endolysin having at least 95% sequence identity to the nucleic acid sequence shown in SEQ ID NO: 1 or to the amino acid sequence shown in SEQ ID NO: 2.

Claims (11)

1. A tobacco product comprising an effective amount of a composition, wherein the composition comprises a bacteriophage comprising a nucleic acid sequence encoding an endolysin, wherein the endolysin comprises at least 95% sequence identity to the amino acid sequence shown in SEQ ID NO: 2, and wherein the effective amount is an amount of the bacteriophage that is sufficient to reduce the number of a viable bacteria in the tobacco product relative to a tobacco product in the absence of the composition.

2. The tobacco product of claim 1 , wherein the nucleic acid sequence has at least 98% sequence identity to the nucleic acid sequence shown in SEQ ID NO: 1.

3. The tobacco product of claim 1 , wherein the nucleic acid sequence has at least 99% sequence identity to the nucleic acid sequence shown in SEQ ID NO: 1.

4. The tobacco product of claim 1 , wherein the nucleic acid sequence has the nucleic acid sequence shown in SEQ ID NO: 1.

5. The tobacco product of claim 1 , wherein the endolysin has at least 98% sequence identity to the amino acid sequence shown in SEQ ID NO: 2.

6. The tobacco product of claim 1 , wherein the endolysin has at least 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2.

7. The tobacco product of claim 1 , wherein the endolysin has the amino acid sequence shown in SEQ ID NO: 2.

8. A tobacco product comprising a polypeptide having at least 95% sequence identity to the amino acid sequence shown in SEQ ID NO: 2.

9. The tobacco product of claim 8 , wherein the polypeptide has at least 98% sequence identity to the amino acid sequence shown in SEQ ID NO: 2.

10. The tobacco product of claim 8 , wherein the polypeptide has at least 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 2.

11. The tobacco product of claim 8 , wherein the polypeptide has the amino acid sequence shown in SEQ ID NO: 2.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2017
From: XU, DONGMEI; MILLER, ELISABETH; STRICKLAND, JAMES ARTHUR; WAREK, UJWALA
To: ALTRIA CLIENT SERVICES INC.
Reel/Frame 042376/0336 →
MERGER AND CHANGE OF NAME Recorded May 15, 2017
From: ALTRIA CLIENT SERVICES INC.; ALTRIA CLIENT SERVICES LLC
To: ALTRIA CLIENT SERVICES LLC
Reel/Frame 042376/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2017
From: HAGENS, STEVEN
To: MICREOS BV
Reel/Frame 042376/0550 →
Continuity (3)
Continuation 14205660 · Mar 12, 2014
Provisional Application 61791976 · Mar 15, 2013
Related Publication 20160369245A1 · Dec 22, 2016